The Prevalence of COPD

Stang, Paul; Lydick, Eva; Silberman, C; Kempel, Angela; Keating, Elizabeth T.

doi:10.1378/chest.117.5_suppl_2.354s

Cited by 165 publications

(38 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using smoking rates, 15.3 million people >40 years are estimated to have COPD in the United States. The global prevalence of COPD GOLD stage II and above is about 10% [5, 6]. Furthermore, COPD is expected to rise from the 6th to the 3rd most common cause of death worldwide in 2020 [1, 2].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Measuring FEV<sub>6</sub> for Detecting Early Airway Obstruction in the Primary Care Setting

et al. 2009

View full text Add to dashboard Cite

Background: The prevalence of asthma and chronic obstructive pulmonary disease (COPD) is high (∼7.4–18%) in the general population, but less than half are diagnosed. Several studies have shown FEV₆ as a good surrogate marker for forced vital capacity (FVC) to detect airflow limitations. Objectives: The aim of this study was to evaluate if it is possible to simplify and improve the diagnosis of so far undiagnosed asthma or COPD in the primary care setting by measuring FEV₆ with a new simple screening device (PiKo-6). Methods: 507 patients were recruited from three general practices from May to June 2005. Patients with any known pulmonary disease were excluded by questionnaire. FEV₁, FEV₆ and FEV₁/FEV₆ were determined using a PiKo-6 device. Patients with an FEV₁/FEV₆ <80% (PiKo positive) were invited to a standardized pulmonary function test to confirm or rule out airflow limitation. Results: 401 (79.1%) patients showed FEV₁/FEV₆ ≥80% (PiKo negative), and 106 (20.9%) patients were PiKo positive. Of the 106 PiKo-positive patients, 74 patients (14.7% of total) agreed to further studies and 18 patients (3.6%) of them suffered from COPD [COPD 0: 5 (1.0%); COPD I: 9 (1.8%); COPD II: 4 (0.8%), and none with COPD III or IV] and 14 patients (2.8%) suffered from bronchial hyperresponsiveness or asthma. In 42 patients (8.3%), the pulmonary function test was normal. Conclusions: Measurement of FEV₆ using a new simple screening device (PiKo-6) may improve the detection rate of undiagnosed airflow limitation in the primary care setting. However, patients should be carefully selected.

show abstract

Section: Introductionmentioning

confidence: 99%

“…However, airflow limitation from both asthma and COPD often remains undiagnosed in its early stages [3, 4,7,8,9,10,11,12]. Therefore, early detection of asthma and COPD is an important health issue [3, 5]. …”

Section: Introductionmentioning

confidence: 99%

Measuring FEV<sub>6</sub> for Detecting Early Airway Obstruction in the Primary Care Setting

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The increase in the prevalence of these diseases around the world is largely related to the increase in pollution and tobacco consumption which are the main risk factors and which are constantly increasing in low-income countries [8][9][10]. Although the main cause is active smoking, several studies have focused on the close relationship between these diseases and other risk factors that act from childhood to adulthood, such as genetic factors, passive smoking, childhood pulmonary infections, professional and household exposure [11,12].…”

Section: Introductionmentioning

confidence: 99%

Prevalence of chronic obstructive respiratory diseases amongst fishermen

Laraqui¹,

Hammouda²,

Laraqui³

et al. 2018

International Maritime Health

View full text Add to dashboard Cite

“…1,2 More than 1.5 million adults are known to be diagnosed with COPD in England and Wales, and a further 3 million adults are estimated to be living with undiagnosed COPD. 3,4 Improving the care and outcomes for people with COPD is a priority for the National Health Service (NHS) in England, which aims to reduce premature mortality from respiratory disease, avoid unnecessary hospital admissions and improve the quality of life and support for patients with long-term conditions and their carers. 5 However, several current issues remain in the diagnosis and monitoring of COPD, some of which could be resolved by technological developments or novel disease biomarkers.…”

Section: Introductionmentioning

confidence: 99%

New and emerging technologies for the diagnosis and monitoring of chronic obstructive pulmonary disease

et al. 2016

View full text Add to dashboard Cite

There is a need for straightforward, novel diagnostic and monitoring technologies to enable the early diagnosis of COPD and its differentiation from other respiratory diseases, to establish the cause of acute exacerbations and to monitor disease progression. We sought to establish whether technologies already in development could potentially address these needs. A systematic horizon scanning review was undertaken to identify technologies in development from a wide range of commercial and non-commercial sources. Technologies were restricted to those likely to be available within 18 months, and then evaluated for degree of innovation, potential for impact, acceptability to users and likelihood of adoption by clinicians and patients with COPD. Eighty technologies were identified, of which 25 were considered particularly promising. Biomarker tests, particularly those using sputum or saliva samples and/or available at the point of care, were positively evaluated, with many offering novel approaches to early diagnosis and to determining the cause for acute exacerbations. Several wrist-worn devices and smartphone-based spirometers offering the facility for self-monitoring and early detection of exacerbations were also considered promising. The most promising identified technologies have the potential to improve COPD care and patient outcomes. Further research and evaluation activities should be focused on these technologies.

show abstract

The Prevalence of COPD

Cited by 165 publications

References 19 publications

Measuring FEV<sub>6</sub> for Detecting Early Airway Obstruction in the Primary Care Setting

Measuring FEV<sub>6</sub> for Detecting Early Airway Obstruction in the Primary Care Setting

Prevalence of chronic obstructive respiratory diseases amongst fishermen

New and emerging technologies for the diagnosis and monitoring of chronic obstructive pulmonary disease

Contact Info

Product

Resources

About